|
|
 |
|
 |
|
|
|
|
Title:
|
Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma - IRB# 10-042B
|
|
Treatments:
|
5 FU, Capecitabine, Erlotinib, Fluoropyrimidine, Gemcitabine, RT
|
|
Disease Site:
|
Gastrointestinal
|
|
Disease SubSite:
|
Pancreas
|
|
Drug Provided:
|
Erlotinib
|
|
Comments:
|
|
|
Eligibility:
|
Histologically confirmed primary adenocarcinoma of the pancreatic head, neck, or uncinate process. Intraductal papillary mucinous neoplasm or invasive adenocarcinoma allowed. No non-adenocarcinoma, adenosquamous carcinoma, islet cell (neuroendocrine) tumor, cystadenoma, cystadenocarcinoma, carcinoid tumor, duodenal carcinoma, distal bile duct tumor, or ampullary carcinoma. Pathologic stage T1-3, N0-1, M0 disease according to AJCC 6th edition. Has undergone a potentially curative resection (i.e., removal of all gross tumor) involving a classic (Whipple) or a pylorus preserving pancreaticoduodenectomy within the past 21-56 days. Operative report must contain a statement from the surgeon explicitly detailing that a total gross excision of the primary tumor was achieved. Pathology report must include documentation of margin status, size of the tumor, and status of the 3 major surgical margins (bile duct, pancreatic parenchyma, and retroperitoneal [uncinate]). Post-resection serum CA19-9 =<180 IU/L. Tumor tissue block and peripheral blood samples must be submitted to the study's central tumor bank for correlative studies. No recurrent pancreatic cancer. Prior/Concurrent Therapy: See Disease Characteristics. No prior systemic chemotherapy for pancreatic cancer. Prior chemotherapy for a different cancer allowed. No prior total pancreatectomy, distal pancreatectomy, or central pancreatectomy. No prior radiotherapy to the region of the study cancer that would result in overlap of radiotherapy fields. Concurrent highly active antiretroviral treatment (HAART) allowed.
|
|
Participating Sites:
|
Providence Portland Medical Center, Northwest Cancer Specialists - Vancouver
|
|
|
|
|
 |
|
 |
|
|
|